Prognosis in Breast Cancer

  • W. L. McGuire
  • G. M. Clark
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 115)


Only one-half of patients presenting with primary breast cancer are cured by local therapy. It is thus desirable to have a method to predict which patients are likely to have a recurrence so that systemic therapy can be instituted to delay, or even prevent, such recurrences. For many years, our laboratory in San Antonio has been measuring factors in human breast cancer patients which have been hypothesized to correlate with clinical outcome. Our efforts have dealt primarily with the prognostic factors listed in Table 1. We will briefly review each of these prognostic factors and provide the essential data which correlates each factor with clinical outcome. In this summary of San Antonio efforts, we will not attempt to review the literature or detail the work of others.


Breast Cancer Progesterone Receptor Axillary Lymph Node Oncogene Amplification Human Breast Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS (1983) Progesterone receptors as a prognostic factor in Stage II breast cancer. N Eng J Med 309: 1343–1347CrossRefGoogle Scholar
  2. Knight WA III, Livingston RB, Gregory EJ, McGuire WL (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37: 4669–4671PubMedGoogle Scholar
  3. McGuire WL, Dressier LG (1985) Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients. J Natl Cancer Inst 75: 405–410PubMedGoogle Scholar
  4. McGuire WL, Meyer JS, Barlogie B, Kute TE (1985) Impact of flow cytometry on predicting recurrence and survival in breast cancer patients. Breast Cancer Res Treat 5: 117–128PubMedCrossRefGoogle Scholar
  5. Meyer JS (1986) Cell kinetics in selection and stratification of patients for adjuvant therapy of breast carcinoma, NCI Monogr 1: 25–28PubMedGoogle Scholar
  6. Silvestrini R, Daidone MG, De Fronzo G, Morabito A, Valagussa P, Bonadonna G (1986) Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat 7: 161–169PubMedCrossRefGoogle Scholar
  7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Amplification of the HER-2/neu oncogene correlates with relapse and survival in human breast cancer. Science 235: 177–182PubMedCrossRefGoogle Scholar
  8. Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP (1984) The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer 33: 441–445PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1989

Authors and Affiliations

  • W. L. McGuire
    • 1
  • G. M. Clark
    • 1
  1. 1.Department of Medicine, Division of OncologyUniversity of Texas Health Science CenterSan AntonioUSA

Personalised recommendations